1. Home
  2. NEN vs SGMT Comparison

NEN vs SGMT Comparison

Compare NEN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

NEN

New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

HOLD

Current Price

$59.55

Market Cap

209.2M

Sector

Real Estate

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$7.06

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEN
SGMT
Founded
1977
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
209.2M
169.4M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
NEN
SGMT
Price
$59.55
$7.06
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$26.13
AVG Volume (30 Days)
653.0
781.4K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
2.71%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$89,196,544.00
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.68
N/A
Revenue Growth
10.76
N/A
52 Week Low
$56.00
$4.50
52 Week High
$74.00
$11.41

Technical Indicators

Market Signals
Indicator
NEN
SGMT
Relative Strength Index (RSI) 50.01 55.64
Support Level $56.83 $6.26
Resistance Level $60.90 $7.20
Average True Range (ATR) 0.81 0.33
MACD 0.05 0.05
Stochastic Oscillator 60.29 76.82

Price Performance

Historical Comparison
NEN
SGMT

About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating, and selling real estate. The Partnership owns and operates various residential apartments, condominium units, and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent, and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: